Claims
- 1. A method of treating Parkinson's disease in a primate, comprising:
a) providing recombinant adeno-associated virus (rAAV) virions comprising heterologous genes encoding dopamine synthesizing enzymes wherein said dopamine synthesizing enzymes comprise tyrosine hydroxylase, aromatic L-amino acid decarboxylase, and guanosine triphosphate cyclohydrolase I; and b) administering to said primate said rAAV virions wherein at least one corpus striatal cell of said primate is transduced; and c) expressing said heterologous genes wherein expression results in a therapeutic effect in said primate.
- 2. The method of claim 1, wherein said corpus striatal cell is a putamen cell.
- 3. The method of claim 1, wherein said corpus striatal cell is a caudate nucleus cell.
- 4. The method of claim 1, wherein at least one putamen cell and at least one caudate nucleus cell are transduced.
- 5. The method of claim 1, wherein said therapeutic effect in said primate is an improvement in fine motor tasking.
- 6. The method of claim 1, wherein said therapeutic effect in said primate is an improvement in manual dexterity.
- 7. The method of claim 1, wherein said therapeutic effect in said primate is a reduction is resting tremor.
- 8. The method of claim 1, wherein said primate is a human.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is related to provisional patent application Ser. No. 60/275,903, filed Mar. 14, 2001 entitled “Behavioral Recovery in a Primate Model of Parkinson's Disease by Triple Transduction of Striatal Cells with AAV Vectors Expressing Dopamine-Synthesizing Enzymes” from which application priority is claimed under 35 USC §119(e)(1).
Provisional Applications (1)
|
Number |
Date |
Country |
|
60275903 |
Mar 2001 |
US |